HTSUY (Hisamitsu Pharmaceutical Co) Research & Development: $0 Mil (TTM As of Nov. 2025)


HTSUY Hisamitsu Pharmaceutical Co Inc HTSUY
84 GF Score
Price $2.94
GF Value $5.41
Valuation Significantly Undervalued
View Full Analysis

What is Hisamitsu Pharmaceutical Co Research & Development?

Hisamitsu Pharmaceutical Co HTSUY 84 Research & Development is $0 Mil as of Nov. 2025. GuruFocus rates HTSUY with a GF Score™ of 84/100 and a GF Value™ of $5.41 (Significantly Undervalued).

Research & Development is the aggregate amount of research and development expenses during the year. Hisamitsu Pharmaceutical Co's Research & Development for the three months ended in Nov. 2025 was $0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Nov. 2025 was $0 Mil.

Hisamitsu Pharmaceutical Co  (OTCPK:HTSUY) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Hisamitsu Pharmaceutical Co Research & Development Related Terms

Hisamitsu Pharmaceutical Co Research & Development Historical Data

* Premium members only.

The historical data trend for Hisamitsu Pharmaceutical Co's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hisamitsu Pharmaceutical Co Research & Development Chart

Hisamitsu Pharmaceutical Co Annual Data
Trend Feb17 Feb18 Feb19 Feb20 Feb21 Feb22 Feb23 Feb24 Feb25 Feb26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Hisamitsu Pharmaceutical Co Quarterly Data
May21 Aug21 Nov21 Feb22 May22 Aug22 Nov22 Feb23 May23 Aug23 Nov23 Feb24 May24 Aug24 Nov24 Feb25 May25 Aug25 Nov25 Feb26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HTSUY
84GF Score
Hisamitsu Pharmaceutical Co Inc HTSUY
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Hisamitsu Pharmaceutical Co Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Nov. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0 Mil mean?
Hisamitsu Pharmaceutical Co (HTSUY) has a Research & Development of $0 Mil as of Nov. 2025. Research and development expense is the total cost for research and development activities. View historical data on Hisamitsu Pharmaceutical Co and its competitors.
Is Hisamitsu Pharmaceutical Co's Research & Development too high?
Hisamitsu Pharmaceutical Co's current Research & Development is $0 Mil. Overall, Hisamitsu Pharmaceutical Co has a GF Score™ of 84/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Hisamitsu Pharmaceutical Co's Research & Development compare to ZTS?
Hisamitsu Pharmaceutical Co's Research & Development of $0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Hisamitsu Pharmaceutical Co and its competitors. Hisamitsu Pharmaceutical Co's current Research & Development is $0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Hisamitsu Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co (HTSUY) is currently considered Significantly Undervalued. The stock's GF Value™ is $5.41, compared to a current price of $2.94 — trading 45.7% below its estimated fair value. The current Research & Development is $0 Mil. Hisamitsu Pharmaceutical Co's overall GF Score™ is 84/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Hisamitsu Pharmaceutical Co (HTSUY), the current Research & Development is $0 Mil as of Nov. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Hisamitsu Pharmaceutical Co (HTSUY) Overvalued in 2026?

Based on GuruFocus' analysis, Hisamitsu Pharmaceutical Co stock appears to be undervalued. The current stock price of $2.94 is trading 45.7% below its estimated GF Value™ of $5.41. GuruFocus considers Hisamitsu Pharmaceutical Co to be Significantly Undervalued.

Key valuation signals for HTSUY:

  • Research & Development: $0 Mil
  • GF Value™: $5.41 vs. price of $2.94 (45.7% below fair value)
  • GF Score™: 84/100

No single metric tells the full story. See the HTSUY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Hisamitsu Pharmaceutical Co Business Description

Address 408 Tashiro Daikancho, Saga Prefecture, Tosu, JPN, 841-0017
Hisamitsu Pharmaceutical Co Inc is engaged in the research, development, manufacturing, procurement, and sale of pharmaceutical products. The company operates a single business segment, focusing on medical and general pharmaceuticals both in Japan and overseas. It markets drugs under the Salonpas, Nobinobi / Salonsip, Butenalock, and Mohrus brands, which mainly serve topical medication needs with pain relief creams, gels, sprays, lotions, and ointments.
84GF Score

Get the complete analysis for HTSUY

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.94
Price
$5.41
GF Value